

1 **Immune signature of patients with cardiovascular disease – in-depth**
2 **immunophenotyping predicts increased risk for a severe course of COVID-19**

3 Manina Günter^{1,2*}, Karin Anne Lydia Mueller^{3*}, Mathew Salazar², Sarah Gekeler³, Carolin
4 Prang³, Tobias Harm³, Meinrad Paul Gawaz³, and Stella E. Autenrieth^{1,2}

5
6 ¹University Hospital Tuebingen, Department of Hematology, Oncology, Clinical Immunology
7 and Rheumatology, Eberhard Karls University Tuebingen, Tuebingen, Germany

8 ²German Cancer Research Centre, Research Group Dendritic Cells in Infection and Cancer,
9 F171, Heidelberg, Germany

10 ³University Hospital Tuebingen, Department of Cardiology and Angiology, Eberhard Karls
11 University Tuebingen, Tuebingen, Germany

12 * These authors contributed equally

13

14 **Corresponding author:**

15 Stella E. Autenrieth, PhD

16 German Cancer Research Centre,
17 Research Group Dendritic Cells in Infection and Cancer, F171,
18 Im Neuenheimer Feld 280, 69121 Heidelberg, Germany

19 Tel: +49-6221-42-1290

20 E-mail: stella.autenrieth@dkfz.de

21

22 **Short title:** Immune signature predicts COVID-19 disease progression

23 **Keywords:** cardiovascular disease; SARS-CoV-2 infection; COVID-19; spectral flow
24 cytometry; immuno-response; immune signature

1 **Abstract**

2 **Objective:** SARS-CoV-2 infection can lead to life-threatening clinical manifestations.
3 Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-
4 19. However, strategies to predict the course of SARS-CoV-2 infection in CVD patients at
5 hospital admission are still missing. Here, we investigated whether the severity of SARS-
6 CoV-2 infection can be predicted by analyzing the immunophenotype in the blood of CVD
7 patients.

8 **Approach and Results:** We prospectively analyzed the peripheral blood of 94 participants,
9 including CVD patients with acute SARS-CoV-2 infection, uninfected CVD patients, and
10 healthy donors using a 36-color spectral flow cytometry panel. Clinical assessment included
11 blood sampling, echocardiography, and electrocardiography. Patients were classified by their
12 ISARIC WHO 4C-Mortality-Score on the day of admission into three subgroups of an
13 expected mild, moderate, or severe course of COVID-19. Unsupervised data analysis
14 revealed 40 clusters corresponding to major circulating immune cell populations. This
15 revealed little differences between healthy donors and CVD patients, whereas the distribution
16 of the cell populations changed dramatically in SARS-CoV-2-infected CVD patients. The
17 latter had more mature NK cells, activated monocyte subsets, central memory CD4⁺ T cells,
18 and plasmablasts than uninfected CVD patients. In contrast, fewer dendritic cells, CD16⁺
19 monocytes, innate lymphoid cells, and CD8⁺ T cell subsets were detected in SARS-CoV-2-
20 infected CVD patients. We identified an immune signature characterized by low frequencies
21 of MAIT and intermediate effector CD8⁺ T cells in combination with a high frequency of NKT
22 cells that is predictive for CVD patients with a severe course of SARS-CoV-2 infection on
23 hospital admission.

24 **Conclusion:** Acute SARS-CoV-2 infected CVD patients revealed marked changes in
25 abundance and phenotype of several immune cell populations associated with COVID-19
26 severity. Our data indicate that intensified immunophenotype analyses can help identify
27 patients at risk of severe COVID-19 at hospital admission, improving clinical outcomes
28 through specific treatment.

29

1 **Highlights**

- 2 • Patients with cardiovascular disease are at higher risk of severe courses of COVID-
3 19 and may exhibit an altered immune response
- 4 • Unsupervised data analysis revealed that patients with cardiovascular disease and
5 SARS-CoV-2 infection showed significant changes in the abundance and the
6 phenotype of various immune cell populations
- 7 • We identified a disease-related immune signature in patients with cardiovascular
8 disease and SARS-CoV-2 infection associated with the severity of COVID-19
- 9 • Intensified immunophenotyping helps to identify cardiovascular patients at risk of a
10 severe course of COVID-19 already at the early stages of the disease and might
11 thereby improve clinical outcomes and specific treatment of COVID-19

12

13

1 1. Introduction

2 Coronavirus disease 2019 (COVID-19) refers to a broad spectrum of clinical manifestations
3 caused by infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-
4 CoV-2). The severity of the disease is related to risk factors such as age, sex, and pre-
5 existing comorbidities^{1,2} that correlate with the immune response during acute infection^{1,2}.
6 SARS-CoV-2 infection ranges from asymptomatic to fatal courses. In patients recovering
7 from a non-severe infection, the immune system responded to SARS-CoV-2 infection with
8 robust, broad-based, and transient regulatory features³⁻⁶. In contrast, severe COVID-19 is
9 characterized by hyperactivation of innate but also adaptive immune cells, an exuberant
10 cytokine response, and high titers of SARS-CoV-2-specific antibodies^{4,5,7,8}.

11 Common complications in hospitalized patients infected with SARS-CoV-2 include
12 pneumonia, sepsis, acute respiratory distress syndrome (ARDS), and respiratory failure⁹⁻¹¹.
13 The pathophysiology of SARS-CoV-2 is characterized by an early production of pro-
14 inflammatory cytokines (e.g., tumor necrosis factor (TNF), IL-6, and IL-1 β), often resulting in
15 hyperinflammation¹². This so-called cytokine storm increases the risk of vascular
16 hyperpermeability and, if persistent, multi-organ failure and eventual death¹¹.

17 Patients with cardiovascular disease (CVD) are critically susceptible to more severe courses
18 of SARS-CoV-2 infection, which may lead to life-threatening complications like cardiac and
19 pulmonary damage as the most common complications^{13,14}. For example, an enhanced pro-
20 inflammatory and pro-thrombotic immune response, characteristic of SARS-CoV-2 infected
21 patients with pre-existing CVD, can trigger myocarditis or acute coronary syndrome with
22 subsequent congestive heart failure¹⁵⁻¹⁹. Furthermore, CVD patients are prone to ARDS and
23 progressive respiratory failure and along with an increased risk of a pulmonary embolism due
24 to infection-associated coagulopathy, which may cause not only acute right heart failure but
25 also disseminated intravascular coagulation¹⁹. These clinical scenarios explain the
26 increased rate of unfavorable clinical outcomes like organ failure, admission to the intensive
27 care unit (ICU) with rapidly progressive respiratory failure, and mortality in CVD patients with
28 SARS-CoV-2 infection^{14,15,17}

29 CVD is characterized by alterations in inflammatory mediators like C-reactive protein (CRP),
30 pro-inflammatory cytokines and chemokines, platelet and monocyte activation, and
31 enhanced expression of adhesion molecules on endothelial and immune cells are critical
32 players of atherogenesis and -progression²⁰⁻²². Up-regulation of the involved cytokines and
33 chemokines and platelet activation recruits inflammatory cells like monocytes, macrophages,
34 and dendritic cells to the arterial wall causing atherosclerotic lesions²¹. In addition, pro-
35 inflammatory adaptive immune cells like Th1 and Th17 cells are also critically involved in
36 CVD, especially myocardial infarction, myocarditis, and heart failure²³⁻²⁵. Due to a

1 chronically enhanced pro-inflammatory immune response, patients with CVD are at risk for a
2 severe course of COVID-19. However, strategies to identify these high-risk patients with
3 CVD early in COVID-19 are still lacking. Thus, there is still an urgent clinical need to
4 understand the complexity of the innate and adaptive immune system dysfunctions that
5 underlie severe or even fatal COVID-19 in this subgroup of CVD patients to provide the best
6 possible care upon hospitalization and improve clinical outcomes. In the present study, we
7 aimed to identify the critical immune system components to predict a severe course of
8 COVID-19 in CVD patients. Accordingly, we performed in-depth analyses of innate and
9 adaptive immune cells and cytokines in the peripheral blood of CVD patients with and without
10 acute SARS-CoV-2 infection. Our study revealed that a complex but specific immune
11 signature is associated with the severity of COVID-19 in patients with CVD and can predict
12 the course of the disease already upon first admission to the hospital.

1 **2. Methods**

2 **Study design, participants, and assessment of clinical parameters**

3 From March to April 2020, we prospectively studied a consecutive cohort of 94 participants at
4 the Department of Cardiology and Angiology of the University Hospital Tübingen, Germany.
5 Of these, 37 consecutive patients with pre-existing CVD and symptomatic, acute SARS-CoV-
6 2 infection (CVD+SARS-CoV-2) were admitted to our emergency department. Twenty
7 patients with pre-existing stable CVD without any infections were matched for the group of
8 CVD+SARS-CoV-2 patients. 37 healthy donors (HD) served as controls (Table 1 and Tables
9 S1-2). All patients underwent clinical and cardiac assessment, including echocardiography,
10 electrocardiography, concomitant medication, comorbidities, and blood sampling for routine
11 laboratory parameters within 12 hours of admission. SARS-CoV-2 infection was diagnosed
12 by RNA detection from nasopharyngeal secretions with real-time reverse transcriptase
13 polymerase chain reaction. Pre-existing CVD was defined as stable coronary artery disease,
14 which had been determined by coronary angiography and diagnosed when there was luminal
15 stenosis of one or more coronary vessels >25-50% diameter before hospital admission.
16 Respiratory failure was defined by a Horovitz Index (HI) \leq 200 mmHg.²³

17 The inclusion criteria for our study were confirmed CVD with or without SARS-CoV-2
18 infection and an age \geq 18 years. Exclusion criteria were other viral or bacterial infections and
19 malignancies. The study was approved by the local ethics committee (240/2018BO2) and
20 complied with the Declaration of Helsinki and the Good Clinical Practice Guidelines on the
21 approximation of the laws, regulations, and administrative provisions of the Member States
22 relating to the implementation of good clinical practice in the conduct of clinical trials on
23 medicinal products for human use. Written informed consent was obtained from each patient.

24 N terminal-pro-B-type natriuretic peptide (NT-pro-BNP, >300 ng/L), high sensitive troponin I
25 (hs TNI, >37 ng/L), and C-reactive protein (CRP, >0.5 mg/dL) were classified as elevated
26 laboratory markers of myocardial and inflammatory distress. Echocardiographic parameters
27 included left and right ventricular function, right ventricular dilatation, presence of tricuspid
28 valve regurgitation, and pericardial effusion according to current guidelines.^{24,25}

29 **Isolation of peripheral blood mononuclear cells**

30 Blood samples of patients with CVD (including SARS-CoV-2 infection) and HD were
31 collected in CPDA monovettes and were processed within 4 hours after blood collection.
32 Peripheral blood mononuclear cells (PBMCs) were isolated using SepMate tubes (Stem Cell
33 Technologies) according to the manufacturer's instructions by density gradient centrifugation
34 at 1200 x g for 10 min at room temperature with 25 mL cell suspension (blood diluted with
35 PBS 1:1) stacked on 15 mL Biocoll separation solution (Biochrom). The clear supernatant

1 containing the PBMCs was decanted and washed three times with PBS+2% FCS. PBMCs
2 were frozen as aliquots of $1-2 \times 10^7$ cells in RPMI1640 containing 20% FBS and 10% DMSO
3 at -150°C until further use.

4 **Flow Cytometry staining**

5 PBMCs were thawed in a water bath at 37°C , followed by adding 10 ml RPMI (Sigma)
6 containing 50 KU DNaseI (Merck). Cells were centrifuged at $400 \times g$ for 5 minutes at room
7 temperature. The supernatant was discarded, and the cells were resuspended in 5 ml RPMI
8 containing 200 KU DNaseI and incubated for 20 minutes at 37°C . The cell numbers were
9 determined by trypan blue exclusion using a Neubauer counting chamber. Cells were
10 washed once with PBS, and 3×10^6 cells were stained with LIVE/DEAD Fixable Blue Dead
11 Cell Stain Kit (Thermo Fisher Scientific) according to the manufacturer's instructions to
12 exclude dead cells (final dilution 1:1000). All following washing and incubation steps were
13 performed with Cell Staining Buffer (BioLegend). Blocked Cells were incubated with Human
14 True StainFcX (BioLegend) at room temperature for 10 minutes to prevent unspecific binding
15 of antibodies to Fc receptors. After that, extracellular staining was performed for 1 hour at
16 4°C using the antibodies listed in Table S3, in a final volume of 100 μl containing 5 μl True-
17 Stain Monocyte Blocker (BioLegend) to block non-specific binding of PE/Dazzle594, PE/Cy5,
18 PE/Cy7, APC/Cy7, and APC/Fire750 to monocytes. Cells were washed twice with staining
19 buffer, and at least 1.5×10^6 cells were acquired using an Aurora (Cytex Bioscience) with the
20 SpectroFlow software. Unmixing was performed in SpectroFlow using cell- or bead-based
21 single-stain controls and unstained cells for autofluorescence subtraction.

23 **Flow Cytometry data analysis**

24 We performed a classical gating strategy (Supplemental Figure 1) for quality control of the
25 36-color panel and unsupervised data analysis described below using OMIQ software
26 (Dotmatics, Boston, MA, USA). First, the compensation and the scaling were set, followed by
27 a subsampling to 1.5×10^6 events/sample. FlowAI was run (flow rate: second fraction 0.1;
28 alpha 0.01; and dynamic range: both limits with negative value removal limit 1) including
29 time, all fluorescent channels, and autofluorescence followed by gating and subsampling on
30 1×10^6 flowAI passed cells/group (HD, CVD or CVD+SARS-CoV2). The data were normalized
31 using fdaNorm for all fluorescent channels, followed by adjusting the scaling where needed
32 and gating on and subsampling of living 5×10^5 CD45⁺ cells per group. Subsequently,
33 dimensionality reduction analysis was performed using Uniform Manifold Approximation and
34 Projection (UMAP) to visualize the different sub-populations of the cells.²⁵ UMAP settings
35 were as follows: all files used, all fluorescent parameters were used except Live/Dead, CD45
36 and autofluorescence, Neighbors = 80, Minimum Distance = 0.7, Components = 2, Metric =

1 Euclidean, Learning Rate = 1, Epochs = 200, Random Seed = 5733, Embedding Initialization
2 = spectral. Following the UMAP^{26,27} analysis, FlowSOM²⁷ was run to cluster the data.
3 FlowSOM settings were as follows: all files used, clustering features CD16, CD11c, CD56,
4 CD8, CCR7, CD123, IgD, CD3, CD20, IgM, IgG, CD28, CD141, CD57, CD14, TCR $\gamma\delta$, CD25,
5 CD4, CD27, CD1c, CD19, CD127, HLA-DR, CD38, umap_1, umap_2, xdim = 25, ydim = 25,
6 # of training iterations = 10, Distance Metric = euclidian, consensus metaclustering with k =
7 100, Random Seed = 3919. A heatmap was generated with the metaclusters obtained from
8 FlowSOM and clustered hierarchically using the samples from HD with the medians of all
9 surface markers except for LIVE/DEAD, CD45, and autofluorescence with a euclidean row
10 distance and a ward row leakage to assign the metaclusters to the cell populations.

11

12 **Determination of plasma levels of cytokines/chemokines (LEGENDPlex)**

13 Two LEGENDPlex (Inflammation Panel 1 and Pro-inflammatory Chemokine Panel;
14 BioLegend, San Diego, California, USA) were performed to quantify the concentrations of
15 several chemokines and cytokines in human plasma. Sixty-nine frozen plasma samples were
16 analyzed, consisting of 27 HD, 15 CVD, and 27 SARS-CoV-2-infected CVD patients. The
17 assays were performed according to the manufacturer's manual. A FACS Lyric (BD
18 Biosciences, Franklin Lakes, New Jersey, USA) was used for the measurement. Data
19 analysis was performed with the LEGENDPlex Data Analysis Software (BioLegend, San
20 Diego, California, USA).

21

22 **Statistical analysis**

23 We determined clinical and laboratory baseline characteristics in relation to measured
24 immune cell phenotypes, marker expression, and clinical outcome. Continuous, not normally
25 distributed variables are expressed as median with standard deviation and were compared
26 using unpaired two-tailed Mann–Whitney *U* test for two-group comparison or Kruskal Wallis
27 non-parametric test with Dunn's post-test for three-group comparison. Categorical data are
28 presented as total numbers and proportions and were analyzed by chi-squared test.
29 Correlation analysis was performed by Spearman rank correlation coefficient *r*. To
30 summarize, correlations of essential parameters in CVD patients with and without SARS-
31 CoV-2 infection matrices were generated using Rstudio "Corrplot," displaying correlations of
32 cytokines with or without cell populations from the unsupervised data analysis. Spearman's ρ
33 is colored, and color intensity and size are plotted proportionally to correlation coefficients.

34 The "CombiROC" package was used in Rstudio to determine the optimal combination of cell
35 populations to differentiate mild from severe or moderately SARS-CoV-2-infected CVD

1 patients.^{28,29} Orthogonal partial least-square discriminant analysis (OPLS-DA) was performed
2 using the “MetaboAnalyst” package in RStudio.
3 Comparisons were considered statistically significant if the two-sided p-value was <0.05.
4 Statistical analysis was performed using Prism Software Version 9.4.1 (GraphPad).
5

1 **Results**

2 **Clinical characteristics of patients with cardiovascular disease and symptomatic acute** 3 **SARS-CoV-2 infection**

4 We prospectively studied a cohort of 94 participants from February to April 2020. This cohort
5 consisted of 20 patients with pre-existing CVD and 37 with pre-existing CVD and
6 symptomatic acute SARS-CoV-2 infection. 37 HD served as controls. The baseline
7 characteristics and demographics of the overall cohort are given in **Table 1**. The population's
8 median age was 58 (IQR 42–74) years, and 45 (47.9%) patients were men. Detailed
9 information on every subgroup of the cohort is given in Table S1. Out of 37 CVD+SARS-
10 CoV-2 patients, 20 showed respiratory failure with HI \leq 200 mmHg, while 11 (29.7%) were
11 admitted to the ICU due to progressive respiratory, circulatory, or multi-organ failure.
12 CVD+SARS-CoV-2 patients were further stratified by their ISARIC-WHO-4C-Mortality-Score
13 into a group of expected mild, moderate, or severe course of COVID-19, patients'
14 characteristics stratified by ISARIC-WHO-4C-Mortality-Score are depicted in Table S2.
15 Patients with expected mild COVID-19 were significantly younger ($p=0.016$) than those with
16 an expected moderate or severe disease course. Interestingly, cardiovascular risk factors
17 were equally distributed among the three groups, whereas laboratory parameters like
18 lymphocyte count, CRP, and interleukin-(IL-)6 levels showed significant alterations.

19 **Characterization of immune cell subsets in peripheral blood using a 36-color spectral** 20 **flow cytometry panel**

21 Frozen peripheral blood mononuclear cells (PBMCs) from the described patient cohort were
22 stained with a 36-color antibody panel (**Suppl. Figure 1**) related to a previously published
23 panel³⁰ and measured with a spectral flow cytometer (Aurora, Cytex) to characterize all
24 common immune cell subsets (**Fig. 1A**). Data analysis was performed classically by manual
25 gating (**Suppl. Figure 2**) as well as by unsupervised analysis using Uniform Manifold
26 Approximation and Projection (UMAP)²⁶ for dimensionality reduction followed by clustering
27 using self-organized map (FlowSOM)²⁷ (**Figure 1C**). Already in the UMAP visualization
28 differences were seen between the concatenated files of the different groups of the cohort
29 (**Figure 1B**). FlowSOM clustering was performed with 100 metaclusters (MCs) to identify cell
30 populations with lower abundance, such as cDC1. 13 of these 100 MCs were excluded for
31 further analysis as the percentage of cells in these MCs was less than 0.01. FlowSOM
32 clustering in combination with UMAP plots displaying the expression of one lineage marker
33 on the color-coded x-axis (**Suppl. Figure 3**) and a clustered heatmap showing the median
34 expression of the analyzed markers (**Figure 1D**) was used to assign the obtained 87 clusters
35 to distinct cell populations (**Figure 1C**). Finally, the 36-color staining followed by
36 unsupervised data analysis revealed the discrimination of 40 manually assigned specific cell

1 populations reflecting the manual gating strategy. These cell populations include B cell (lilac),
2 CD4⁺ (orange) and CD8⁺ T cell (blue), NK cell (green), monocyte (pink), and dendritic cell
3 subsets (cDCs, violet), innate lymphoid cells (ILCs, light green) and MAIT cells (turquoise) as
4 well as basophils (yellow) and also neutrophils (purple).

5

6 **SARS-CoV2-infected CVD patients showed significant differences in the distribution** 7 **and the phenotype of immune cell populations compared to uninfected CVD patients**

8 Next, we assessed the differences in the abundance of the 87 MCs obtained by FlowSOM
9 (annotated to 40 different cell populations as described in **Fig. 1**) in PBMCs from HD and
10 CVD patients with and without SARS-CoV2 infection (**Suppl. Figure 4**). Comparison of HD
11 and uninfected CVD patients revealed a reduced frequency of clusters assigned to $\gamma\delta$ T
12 cells, MAIT cells, naïve CD8⁺ T cells, early-like effector memory CD4⁺ T cells (CD4⁺ early-like
13 T_{em}), CD4⁺CD8⁻ T cells, and naïve B cells in CVD patients. In contrast, clusters representing
14 more innate inflammatory cells like CD14⁺ monocytes, neutrophils, mature NK cells, and
15 CD8⁺ central memory T cells (CD8⁺ T_{cm}) were increased in frequency in CVD patients
16 compared to HD (**Suppl. Figure 5**).

17 During symptomatic, acute SARS-CoV-2 infection in hospitalized CVD patients, we observed
18 significant changes in their immune signature compared to uninfected CVD patients,
19 particularly a greater proportion of mature NK cells (MC33), CD14⁺CD16⁺ monocytes (MC11,
20 MC35), activated populations of CD14⁺CD45RA⁺ monocytes (MC27, MC50, MC63), CD4⁺
21 T_{cm} cells (MC97) expressing CD38⁺, CD8⁺ early T_{em} cells (MC60) expressing HLA-
22 DR⁺CD38⁺PD-1⁺ as well as plasmablasts (MC31, MC39) (**Figure 2B**). In contrast, reduced
23 proportions of ILCs (MC62), dendritic cell subsets cDC1 (MC14) and cDC2 (MC13), CD16⁺
24 monocytes (MC23, MC34), less activated/mature CD14⁺ monocytes (MC28, MC45, MC59),
25 as well as CD4⁺CD8⁺ T cells (MC76), naïve, central memory, and early effector-memory
26 CD8⁺ T cells (MC67, MC68, MC61) and CD4⁺ T_{regs} (MC100) were observed in SARS-CoV2-
27 infected compared to uninfected CVD patients (**Figure 2**). To complement our unsupervised
28 analysis, we applied manual gating (**Suppl. Figure 2**) for immune cell subsets contributing to
29 SARS-CoV-2 infection. Similar to the unsupervised data analysis results, we found increased
30 numbers of CD14⁺CD16⁺ intermediate monocytes and plasmablasts and, although not found
31 in the unsupervised data analysis, increased numbers of CD4⁺ T_{emra} cells in SARS-CoV2-
32 infected CVD patients (**Suppl. Figure 6**). The numbers of ILCs, dendritic cell subsets pDCs,
33 cDC1, and cDC2 (not statistically significant), CD16⁺ monocytes, as well as naïve, central
34 memory, and early effector-memory CD4⁺ and CD8⁺ T cells and CD4⁺ T_{regs}, were reduced in
35 SARS-CoV-2 infected compared to uninfected CVD patients. Moreover, fewer numbers of T

1 helper 17 (T_{h17}) and follicular T helper (T_{fh}) cells and $\gamma\delta$ T cells were detected upon SARS-
2 CoV-2 infection.

3 In addition to changes in the proportion of immune cells, we also observed phenotypical
4 changes in SARS-CoV-2 infected CVD patients compared to uninfected CVD patients
5 (**Suppl. Figure 7**). In particular, an overall activation of innate immune cells was observed.
6 For example, the expression of CD38, CD95, and CCR5 was significantly increased on NK
7 cell subsets of SARS-CoV-2 infected CVD patients. Plasmacytoid DCs, important in viral
8 infections due to their type I interferon response ³¹, also showed a significantly more
9 activated phenotype by increased expression of CCR7, CD38, and CD95. Similar effects
10 were observed for basophils and innate lymphocyte cells (ILCs) with increased expression of
11 CD38, CD95, and CXCR3 or CD45RA, CD28, and CD25, respectively.

12 In contrast, the cDC subsets from SARS-CoV-2 infected CVD patients showed less
13 expression of HLA-DR and CD38 but increased expression of CCR5, CCR7, CD11b,
14 CD45RA, and IgG (cDC2s) (**Suppl. Figure 7**), indicating cellular activation and migration, but
15 also an association with a reduced antigen presentation capacity. Regarding the monocyte
16 clusters, we observed an increased migratory and activated phenotype in SARS-CoV-2
17 infected CVD patients, determined by the high expression of CCR7 in all monocyte subsets.
18 However, monocyte subsets from these patients revealed a less activated phenotype than
19 their uninfected CVD counterparts, shown by significantly less expression of HLA-DR, CD38,
20 CD11b (on CD14⁺ monocytes), and CD45RA. Most strikingly, we found an enhanced
21 expression of the thrombin receptor CD141 on monocyte clusters from SARS-CoV-2 infected
22 patients, possibly aiming toward impaired blood coagulation ³².

23 Concerning the adaptive immune cell populations, a more inhibitory phenotype was observed
24 in SARS-CoV2-infected CVD patients compared to uninfected (**Suppl. Figure 7**). The only
25 exception was the plasmablasts. Plasmablasts revealed reduced expression of the apoptotic
26 marker CD95 combined with increased CD38 expression, indicating a more functional and
27 long-living phenotype upon SARS-CoV2 infection. Similar to DCs, a phenotype with
28 decreased activation was observed in the B-cell subsets of SARS-CoV2-infected CVD
29 patients. This was evidenced by lower CD38, HLA-DR, CCR6, CD45RA, and IgD expression.
30 CD8⁺ and most CD4⁺ T cell subsets showed an overall increase in CD38 expression,
31 indicating activation upon SARS-CoV2 infection. However, the inhibitory molecule PD-1 on
32 the cell surface of CD4⁺ and CD8⁺ naïve and T_{cm} cells, CD4⁺ T_{regs}, and HLA-DR⁺CD8⁺
33 activated T cells was increased, which was accompanied by less expression of the co-
34 stimulatory molecule CD28 on CD8⁺ T cell subsets. CXCR3 expression was also reduced on
35 several CD4⁺ and CD8⁺ T cell subsets of SARS-CoV-2 infected compared to uninfected CVD
36 patients. The latter two observations hint towards an impaired migratory capacity and full T

1 cell activation of CD4⁺ and CD8⁺ T cell subsets. In summary, our data show an infection-
2 induced activation of innate immune cells in combination with reduced numbers and
3 inhibitory phenotypes of DCs and adaptive immune cells in infected compared to uninfected
4 CVD patients.

5

6 **Chemokine and cytokine profiling showed significant differences between SARS-CoV- 7 2 infected and uninfected CVD patients**

8 In addition to spectral flow cytometry, 25 common cytokines and chemokines were analyzed
9 in plasma samples from HD and CVD patients without and with SARS-CoV-2 infection, the
10 latter being further subdivided into groups with expected mild and severe course of COVID-
11 19 based on the ISARIC-WHO-4C-Mortality-Score. In line with other studies, the pro-
12 inflammatory cytokines IL-6 and IL-18 were significantly increased in the plasma of SARS-
13 CoV-2 infected compared to uninfected CVD patients and HD (**Suppl. Figure 8A**)^{33,34}.
14 Furthermore, IL-6 was also elevated in CVD patients compared to HD and significantly
15 increased in severe compared to mild SARS-CoV2-infected CVD patients (**Suppl. Figure**
16 **8A&B**). Interestingly, TNF, IL-1b, IL-12p70, IL-23, and IL-33 were lower in SARS-CoV-2
17 infected CVD patients than uninfected CVD patients and HD, indicating impaired T helper
18 cell differentiation in this subgroup. In contrast, the chemokines CCL2 and the CXCR3
19 ligands CXCL9, CXCL10, and CXCL11 were markedly elevated during SARS-CoV-2
20 infection. Differences between mildly and severely affected CVD patients were observed; in
21 particular, a significant increase of IL-6 and IL-8, whereas CCL17, responsible for the
22 recruitment of T cells³⁵, was significantly less abundant in severely infected CVD patients
23 (**Suppl. Figure 8B**). Correlation analysis revealed that predefined cell clusters and
24 chemokine/cytokine profiling showed significant associations among the subgroup of SARS-
25 CoV-2 infected CVD patients and CVD patients without any infections, as depicted in **Suppl.**
26 **Figure 8C**.

27

28 **An immune signature of SARS-CoV-2 infected CVD patients is associated with the 29 severity of COVID-19**

30 SARS-CoV-2 infected CVD patients were classified by their ISARIC WHO 4C-Mortality-Score
31 on the day of admission into three subgroups of an expected mild (4C-Score <4), moderate
32 (4C-Score 4-8), or severe (4C-Score ≥9) course of COVID-19. To determine an association
33 between the immune signature and the severity of COVID-19, we analyzed the abundance
34 and alterations of immune cell populations in the peripheral blood of CVD patients with
35 expected mild, moderate, or severe course of COVID-19. The extent to which the

1 immunophenotype within these three groups may differ was evaluated by spectral flow
2 cytometry as described above.

3 Comparing the frequencies of cells in the above-defined 87 MC from patients with mild and
4 severe or moderate and severe courses of COVID-19 revealed 19 significantly different MCs
5 among the groups (**Figure 3A, Suppl. Figure 9**). These comprised reduced frequencies of
6 neutrophils (MC8, MC16), MAIT cells (MC65, MC69)³⁶, CD14⁺ monocytes expressing high
7 levels of HLA-DR (MC12, MC28), and IgG⁺CD95⁺ B cells (MC25) in severe compared to mild
8 SARS-CoV-2 infected CVD patients. In contrast, a greater proportion of mature NK cells
9 (MC26, MC32), CD45RA⁺CD14⁺ monocytes (MC50), CD8⁺NKT cells (MC55), and several
10 CD4⁺ and CD8⁺ T cell subsets, including CD4⁻CD8⁻HLA-DR⁺ T cells (MC49), naïve CD4⁺ T
11 cells expressing CCR6 and CXCR3 (MC85), central memory (MC79), and effector subsets
12 (MC51, MC87, MC74; **Figure 3**). Interestingly, the percentage of CD14⁺HLA-DR⁺ monocytes
13 expressing high levels of HLA-DR (MC12, MC28), as well as that of CD8⁺ T_{em} (MC51) cells,
14 was reduced in severe compared to moderate SARS-CoV-2 infected CVD patients (**Figure**
15 **3**). In addition to changes in the percentage of immune cell populations in the blood of
16 SARS-CoV-2 infected CVD patients with different severity, we also found differences in the
17 expression pattern of immune markers depending on disease severity (**Suppl. Figure 10**).
18 For example, CD19 was significantly less expressed on MC that represent naïve and
19 memory B cells (MC1, MC2, MC3, MC4, MC19, MC20, MC25, MC21) in SARS-CoV-2
20 infected CVD patients with a severe compared to mild and/or moderate course, indicating
21 less B cell receptor signaling³⁷. Similarly, the expression of the FcγRIII CD16 was reduced on
22 neutrophils (MC7), CD14⁺ (MC12), CD14⁺CD16⁺ (MC11, MC18), CD16⁺ monocytes (MC37),
23 mature NK cells (MC6, MC33), NKT cells (MC41) as well as on CD8⁺ T_{em} and T_{emra} cells
24 (MC51, MC52, MC40, MC46) and CD4⁺ T_{cm} cells (MC79) from CVD patients suffering from
25 severe COVID-19 compared to those with a mild course, indicating less antibody-dependent
26 cellular toxicity and thereby less killing of virus-infected cells (ADCC³⁸). Accordingly,
27 CD14⁺CD16⁺ monocytes from severe SARS-CoV2-infected CVD patients express less HLA-
28 DR on their surface (MC38). The chemokine receptor CXCR3, which is generally
29 upregulated on activated NK and T cells³⁹, had lower expression levels on immune cells from
30 CVD patients with a severe course of COVID-19 namely on neutrophils (MC8), mature NK
31 cells (MC32; MC33), MAIT cells (MC65) and several clusters representing CD4⁺ naïve, T_{cm}
32 and T_{em} cells (MC85, MC93, MC73, MC79, MC95, MC86). CD127 (IL7R α) was significantly
33 less expressed by ILCs (MC62) and CD4⁺CD8⁺ T cells (MC76) from CVD patients with
34 severe SARS-CoV-2 infection as compared to those with mild infection (**Suppl. Figure 10**).
35 In contrast, the latter showed more CCR7 expression (MC76), indicating an altered function
36 of these cells. Furthermore, CD16⁺ monocytes (MC23), naïve CD4⁺ and CD8⁺ T cells (MC84,
37 MC93, MC67) from CVD patients with a severe course of infection, expressed higher levels

1 of CD95 and CD161 (MC84, MC70), combined with lower levels of CD28 expression at least
2 on naïve CD4⁺ T cells (MC85). CD16⁺ monocytes (MC23), naïve CD4⁺ T cells (MC92), and
3 CD4⁺CD8⁺HLA-DR⁺ T cells (MC49) expressed higher levels of CD141 (**Suppl. Figure 10**).

4 In summary, severe SARS-CoV-2 infection resulted in fewer innate immune cells.
5 Interestingly, although an increased proportion of NK cells, CD4⁺ and CD8⁺ T cell subsets
6 were observed in CVD patients with severe COVID-19, their expression of functional markers
7 like CD16 and CXCR3 was impaired, indicating an altered immune response in this
8 subgroup.

9 10 **Immune signature is predictive of severity and the course of SARS-CoV-2 infection in** 11 **patients with pre-existing cardiovascular disease**

12 Next, we looked for an immune signature that has the potential to predict the course of
13 infection at hospital admission. We decided to use a combination of cell populations obtained
14 through unsupervised data analysis that may provide a clear indication of disease
15 progression through a single analysis method. To do this, we first compared the number of
16 cells within different immune cell subpopulations in CVD patients with mild and severe
17 courses as well as moderate and severe courses of SARS-CoV-2 infection (**Figure 4A**).
18 Higher numbers of neutrophils, MAIT cells, and IgG⁺CD95⁺ B cells were found in mild-
19 infected SARS-CoV-2 CVD patients. In contrast, the numbers of NKT cells, plasmablasts,
20 CD4⁺CD8⁺HLA-DR⁺ T cells, and CD4⁺ T_{emra} cells were higher in severely infected SARS-CoV-
21 2 CVD patients (**Figure 4A**). When comparing moderately and severely infected patients,
22 only the intermediate effector CD8⁺ T cells, CD8⁺ NKT cells, and cDC2 were higher in
23 moderately SARS-CoV-2-infected CVD patients (**Figure 4A&B**).

24 After screening for the most relevant differentially abundant immune cell populations in the
25 different patient groups, we used these to search for biomarker combinations to identify
26 subjects at high risk of developing severe COVID-19. This search was performed using the
27 recently published CombiROC package²⁰. Since moderately infected CVD patients may also
28 develop a potentially dramatic course of infection and long-COVID, we also looked for a
29 combination of cell populations that could distinguish this group from the cohort with a mild
30 course. Thus, we used three settings for combined biomarker search: comparisons of (1)
31 mild versus severe (**Figure 4C**), (2) mild versus moderately (**Suppl. Figure 11A**), and (3)
32 mild versus moderately and severely (**Figure 4C**) infected CVD patients. Using CombiROC
33 for the first comparison revealed that a combination of only three cell populations, namely
34 MAIT cells, intermediate effector CD8⁺ T cells and, NKT cells predicts a severe course of
35 SARS-CoV-2-infected CVD patients on hospital admission with a sensitivity and specificity of

1 1 (pink line) (**Figure 4C & Table S4**). The two other comparisons, (2) and (3), did not give
2 quite as good results. In both cases, an area under the curve (AUC) of 0.98 was achieved at
3 best, with a specificity of 1 and a sensitivity of 0.95 and 0.9267, respectively (**Figure 4C &**
4 **Tables S5-S6**). However, a combination of 7 cell populations was necessary in both cases.
5 The distinction between a moderate and a mild course of infection should be possible
6 considering CD4⁺ T_{emra}, CD8⁺ and CD8⁻ NKT cells, CD8⁺HLA-DR⁺CD38⁺ T cells, IgG⁺CD95⁺
7 B cells, neutrophils, and plasmablasts. In the case of predicting a mild compared to a
8 moderate or severe infection course if SARS-CoV-2 infection, a combination of CD4⁺ T_{emra},
9 CD8⁺HLA-DR⁺CD38⁺ T cells, IgG⁺CD95⁺ B cells, neutrophils, plasmablasts, cDC1, and NKT
10 cells is necessary.

11 Correlation analyses were performed between the patient groups' most relevant differentially
12 abundant immune cell populations (see **Figure 4A**) and the corresponding
13 cytokine/chemokine plasma levels. Uninfected CVD patients were characterized mainly by
14 negative correlations, e.g., cDC1s with IFN- α , IL-10, IL-12p70, TNF or CD8⁺HLA-DR⁺CD38⁺
15 T cells with CXCL10 (**Suppl. Figure 11B**). In contrast, SARS-CoV-2-infected CVD patients
16 showed negative correlations of CD8⁺HLA-DR⁺CD38⁺ T cells with CCL5 or cDC2s with
17 CXCL10, IFN- γ , and IL-10 as well as positive correlations like naïve B cells and plasmablasts
18 with CXCL9, IL-10, and IL-18, or IFN- α with IgG⁺CD95⁺ B cells, naïve B cells, and CD8⁺ NKT
19 cells (**Suppl. Figure 11B**). Mildly SARS-CoV-2-infected CVD patients showed positive CD8⁺
20 and CD8⁻ NKT cells correlations with CCL2, CXCL10, CXCL9, IFN- α , IFN- γ , and IL-10, but
21 negative correlations of cDC1 and cDC2 with CXCL10 and IFN- α (**Suppl. Figure 11C**).
22 Significantly fewer and also less pronounced correlations were observed in patients with a
23 moderate course of SARS-CoV2 infection. The positive correlations of IgG⁺CD95⁺ B cells
24 and plasmablasts with IL-10, IL-12p70, IL-18, and, in the latter case, also with IL-6 should be
25 noted. More correlations were generally observed again in the case of a severe SARS-CoV2
26 infection. Here, positive correlations of naïve B cells, plasmablasts, CD8⁺ NKT cells, and
27 neutrophils with CCL2, IFN- α , IFN- γ , IL-17, and IL-6 dominated(**Suppl. Figure 11C**).
28 Moreover, score plots of orthogonal partial least-squares discriminant analysis (OPLS-DA)
29 were performed using immune cell populations and cytokine/chemokine plasma levels from
30 SARS-CoV-2 infected CVD patients (**Figure 4D**). Good between group variance of patients
31 with mild (blue) compared to severe infection (red) points out a major impact of altered
32 immune signatures on the clinical course of the disease.

33 In summary, using high-resolution flow cytometry, we identified an immune cell combination
34 consisting of MAIT cells, intermediate effector CD8⁺ T cells, and NKT cells, stratifying CVD
35 patients at high risk for severe SARS-CoV2 infection on the day of hospital admission.

36

1 Discussion

2 Our study identified a characteristic immune signature of patients with CVD and acute,
3 symptomatic SARS-CoV-2 infection. In contrast to previous investigations, we focussed on
4 patients with pre-existing CVD, which are at high risk of developing progressive
5 cardiopulmonary failure due to the infection^{13–15}. To our knowledge, this is the first analysis
6 to associate a specific immune signature of CVD patients with SARS-CoV-2 infection with
7 the expected severity of COVID-19 during the disease. Here, we identified key immune
8 system components critical to predicting a severe course of COVID-19 in our patient cohort
9 through in-depth analyses of innate and adaptive immune cells^{9,10}. Most other studies that
10 have examined immune cell populations in the blood in SARS-CoV-2 infection have included
11 an all-comers cohort of patients and have not stratified their analyses by concomitant
12 comorbidities, such as diabetes, obesity, asthma, particularly the presence of CVD^{4,5,8,40–45}.
13 Furthermore, these studies focused on patients who either had SARS-CoV2 infection with a
14 mild course or were hospitalized with a moderate-to-severe course. In addition, the previous
15 analysis did not include the expected severity of COVID-19 through associations with
16 established risk scores such as the ISARIC WHO 4C mortality score, another strength of our
17 proposed study.

18 CVD is characterized by an augmented systemic inflammation triggering atherogenesis and -
19 progression and is regulated by platelet and monocyte activation and the secretion of pro-
20 inflammatory mediators, which play a crucial role in cell adhesion and migration²³.
21 Consistent with and in addition to previous studies, we observed changes in the frequencies
22 of innate immune cells like CD14⁺ monocytes, neutrophils, mature NK cells, and MAIT cells,
23 as well as the adaptive immune cells CD4⁺CD8⁺, CD8⁺ naïve and central memory T cells, $\gamma\delta$
24 T cells, early-like effector memory CD4⁺ T cells, and naïve B cell subsets in CVD patients
25 compared to HD^{21,25,45–49}. Moreover, IL-6 levels were increased in CVD patients compared to
26 HD. Thus, a chronic pro-inflammatory response in CVD patients might influence their
27 immune signature compared to HD, leading to a more pronounced immune response to viral
28 infections such as SARS-CoV-2.

29 We show that SARS-CoV-2-infected CVD patients show significant differences in immune
30 cell populations' distribution and phenotype compared to CVD patients without infections.
31 Our data are consistent with other studies regarding, e.g., fewer non-classical monocytes in
32 peripheral blood. These cells were shown to migrate to the site of organ injury, where they
33 maintain the inflammatory processes within cardiac or pulmonary tissue^{40,42,44,46}. As
34 previously reported, we detected a more significant proportion of mature NK cells,
35 CD14⁺CD16⁺ intermediate monocytes, activated populations of CD14⁺CD45RA⁺ monocytes,
36 CD4⁺HLA-DR⁺CD38⁺ and CD8⁺ early T_{em} cells expressing HLA-DR⁺CD38⁺PD-1⁺ cells, as

1 well as plasmablasts upon SARS-CoV-2 infection^{4,5,8,40,42,43}. In contrast, reduced numbers of
2 ILCs, dendritic cell subsets cDC1 and cDC2, less activated/mature CD14⁺ monocytes, and
3 CD8⁺ T cell subsets were observed in SARS-CoV-2 infected compared to uninfected CVD
4 patients^{4,5,8,41,42,47}.

5 Furthermore, we describe phenotypical changes in SARS-CoV-2 infected CVD patients
6 compared to uninfected CVD patients characterized by an overall higher expression of CD38
7 on plasmablasts, monocyte, NK cell, and T cell subsets^{40,42,43} and lower expression of HLA-
8 DR on DCs, CD14⁺ and CD14⁺CD16⁺ monocytes^{4,40,42,46,48}. Moreover, as described for NK
9 cells⁴, less CD16 was expressed on neutrophils, monocyte subsets, NKT cells, CD8⁺ and
10 CD4⁺ T cell subsets from CVD patients with severe COVID-19 compared to those with a mild
11 infection. These data point towards reduced antibody-dependent cellular toxicity, thereby
12 less killing of virus-infected cells (ADCC³⁸). In contrast to Georg et al., we did not detect
13 CD16⁺ activated T cells in severely infected SARS-CoV-2 CVD patients⁴⁹. This may be due
14 to differences in the cohorts (all-comers versus CVD patients) and medication before blood
15 collection (Partial medication such as antibiotics or steroids compared to no medication in
16 our study).

17 Consistent with another study, we found increased expression of the thrombin receptor
18 CD141 on monocyte clusters from SARS-CoV-2 infected CVD patients⁴². CD141 reduces
19 blood coagulation which, among other mechanisms, may be an additional explanation for
20 thromboembolic complications, especially in CVD patients and COVID-19^{32,42,50}.

21 Plasmablasts and B cell subsets revealed a more inhibitory phenotype evidenced by reduced
22 CD19 cell surface expression in SARS-CoV-2-infected CVD patients, whereas the latter was
23 severity-dependent, indicating less B-cell receptor signaling^{8,37}.

24 In addition to other studies, we found that the remaining pDCs, regulating the type I
25 interferon response³¹, also showed a significantly more activated phenotype along with
26 basophils and ILCs in SARS-CoV-2-infected CVD patients. pDCs and cDC subsets from
27 SARS-CoV-2 infected CVD patients revealed a more migratory phenotype evidenced by their
28 increased expression CCR7. In contrast, the chemokine receptor CXCR3, which is generally
29 upregulated on activated NK and T cells³⁹, was less expressed on neutrophils, mature NK
30 cells, MAIT cells, and several CD4⁺ T cell subsets, implicating an impaired migratory capacity
31 of these immune cells. In addition, the ligands for CXCR3, namely CXCL10, and CXCL11,
32 were highly increased upon SARS-CoV-2 infection but also in several other viral infections
33 and correlated with disease severity⁵¹. Thus one explanation for the reduced CXCR3
34 expression on many immune cells is downregulation upon ligand binding⁵². Moreover, naïve
35 CD4⁺ and CD8⁺ T cells from severely-infected CVD patients expressed higher levels of CD95
36 than those from mild-infected ones, indicating an impaired activation due to CD95-mediated

1 inhibition of T-cell receptor signalling⁵³. In summary, our data show an infection-induced
2 activation of innate immune cells combined with reduced numbers and inhibitory phenotypes
3 of DCs and adaptive immune cells in infected compared to uninfected CVD patients.

4 CVD patients with pre-existing cardiac and vascular dysfunction may benefit from intensified
5 heart failure and anti-thrombotic therapy before progression to respiratory failure⁴. Since
6 there is currently limited causal therapy for SARS-CoV-2 infection, early identification and
7 treatment of prognostically relevant comorbidities are critical to prevent a fatal course
8 triggered by the disease. We performed CombiROC analyses to predict the expected
9 severity of COVID-19 at first patient contact based on a specific immune signature analyzed
10 by flow cytometry. These analyses showed that a combination of only three immune cells
11 detected in the blood at hospital admission (NKT cells, MAIT cells, and intermediate CD8⁺
12 effector T cells) is sufficient to distinguish CVD patients with mild from those with a severe
13 course of infection.

14 Including characteristic findings in high-risk CVD patients, such as the specific immune
15 signature, may improve the performance and generalizability of the 4C Mortality Score. This
16 specific immune signature was independently associated with the severity of COVID-19 as
17 determined by the ISARIC WHO 4C mortality score. In addition, there were no confounding
18 factors in the OPLS-DA analysis, such as the comorbidities described above, suggesting that
19 the immune signature may serve as an additional and objective tool for more intensive risk
20 assessment of CVD patients with COVID-19 and increased risk of severe disease
21 progression or infection-related disadvantages or complications, respectively. The ISARIC-
22 WHO-4C mortality score is an easy-to-use, well-validated risk calculator for stratifying
23 patients⁵⁴. However, the data collection of typical cardiovascular comorbidities such as
24 hypertension, previous coronary artery disease, myocardial infarction, and stroke was not
25 included in detail⁵⁵. Therefore, the risk assessment should be further improved for SARS-
26 CoV-2 positive patients with pre-existing CVD, especially for very early stages of the viral
27 infection. Here, we show that a pre-specified, objective analysis of the immune signature can
28 identify CVD patients with an altered immune response at risk for severe courses of viral
29 infections upon first admission or even at asymptomatic stages. These high-risk CVD
30 patients could benefit from intensified monitoring and early anti-inflammatory treatment
31 strategies, thereby preventing long-term ICU treatment or fatal outcomes. Another advantage
32 of the immune signature is good discrimination between mild and severe courses of COVID-
33 19 by an objective laboratory method that is not dependent on the sometimes hard-to-
34 assess, sometimes poorly-defined, clinical parameters associated with unfavorable
35 outcomes.

1 Nevertheless, the study has some limitations. Although we have studied a relatively large
2 cohort of CVD patients with and without SARS-CoV-2 infection and HD, the number of
3 patients with severe courses is limited. We analyzed circulating immune cells and their
4 phenotype, more precise PBMCs. Therefore, we lose a large part of the neutrophil
5 granulocytes in the analysis, shown to be crucial for the distinction between the fatal and
6 non-fatal outcomes of the disease ⁴⁰. And while knowledge of peripheral immune cells is
7 essential for understanding pathogenic and protective immune responses to SARS-CoV-2
8 infection, it does not cover the immune response at the infection site.

9 In conclusion, our study revealed that a specific immune signature is associated with the
10 severity of COVID-19 in patients with CVD and can predict the course of the disease already
11 upon first admission to the hospital. The early determination of the immune signature might
12 enable the treating clinicians to provide the best possible pharmacological and device-based
13 care upon hospitalization and improve clinical outcomes.

14

1

2

3 **Acknowledgment**

4 We thank the Core Facility Flow Cytometry of the Medical Faculty Tübingen for technical
5 help.

6

7 **Sources of Funding**

8 This work was supported by the German Research Foundation (DFG) – Project number
9 374031971–TRR 240 and by the Ministry of Science, Research and the Arts of the State of
10 Baden-Württemberg (Long-COVID Funding). The funder had no role in the study design,
11 data collection, analysis, interpretation, or manuscript writing. The corresponding author had
12 full access to all data in the study and had final responsibility for the decision to submit for
13 publication.

14

15 **Author contributions**

16 MG performed experimental analysis, data acquisition, and preparation of Figures. CP and
17 SG performed the Legendplex analysis. MS and TH analyzed data using R. KALM, and MPG
18 were involved in the conception and design of the study. KALM was responsible for the
19 patient cohort and their classification and manuscript writing. SEA was responsible for the
20 concept and study design, data analysis, data interpretation, drafting of the manuscript,
21 preparation of Figures, and revising it critically for important intellectual content.

22

23 **Conflict of interest**

24 None of the authors has any conflict of interest to declare. Our study complies with the
25 Declaration of Helsinki, our locally appointed ethics committee has approved the research
26 protocol, and informed consent has been obtained from all participants.

27

28 **Data Availability Statement**

29 For original data, please contact Stella E. Autenrieth at stella.autenrieth@dkfz.de.

30

1 References

2

3 1. Koutsakos M, Kedzierska K. A race to determine what drives COVID-19 severity. *Nature*.
4 2020;583(7816):366-368. doi:10.1038/d41586-020-01915-3

5 2. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S, Chen J, Wang W, Chen B,
6 Jiang L, Yu S, Lu J, Wang J, Xu M, Yuan Z, Zhang Q, Zhang X, Zhao G, Wang S, Chen S, Lu H. Viral
7 and host factors related to the clinical outcome of COVID-19. *Nature*. 2020;583(7816):437-440.
8 doi:10.1038/s41586-020-2355-0

9 3. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Sandt CE van de, Jia X, Nicholson S,
10 Catton M, Cowie B, Tong SYC, Lewin SR, Kedzierska K. Breadth of concomitant immune responses
11 prior to patient recovery: a case report of non-severe COVID-19. *Nat Med*. 2020;26(4):453-455.
12 doi:10.1038/s41591-020-0819-2

13 4. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, Agyekum RS,
14 Mathew D, Baxter AE, Vella LA, Kuthuru O, Apostolidis SA, Bershaw L, Dougherty J, Greenplate AR,
15 Pattekar A, Kim J, Han N, Gouma S, Weirick ME, Arevalo CP, Bolton MJ, Goodwin EC, Anderson EM,
16 Hensley SE, Jones TK, Mangalmurti NS, Prak ETL, Wherry EJ, Meyer NJ, Betts MR. Comprehensive
17 mapping of immune perturbations associated with severe COVID-19. *Sci Immunol*.
18 2020;5(49):eabd7114. doi:10.1126/sciimmunol.abd7114

19 5. Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L,
20 Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP, Weisman AR, Ittner CAG, Kuthuru
21 O, Dougherty J, Nzingha K, Han N, Kim J, Pattekar A, Goodwin EC, Anderson EM, Weirick ME,
22 Gouma S, Arevalo CP, Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis
23 SA, Huang AC, Vella LA, Unit TUpCP, Betts MR, Meyer NJ, Wherry EJ, Alam Z, Addison MM, Byrne
24 KT, Chandra A, Descamps HC, Kaminskiy Y, Hamilton JT, Noll JH, Omran DK, Perkey E, Prager EM,
25 Pueschl D, Shah JB, Shilan JS, Vanderbeck AN. Deep immune profiling of COVID-19 patients reveals
26 distinct immunotypes with therapeutic implications. *Science*. 2020;369(6508):eabc8511.
27 doi:10.1126/science.abc8511

28 6. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F,
29 Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment of
30 asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020;26(8):1200-1204. doi:10.1038/s41591-020-
31 0965-6

32 7. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE,
33 Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wylie
34 AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M,
35 Odio CD, Casanovas-Massana A, Obaid A, Lu-Culligan A, Nelson A, Brito A, Nunez A, Martin A,
36 Watkins A, Geng B, Kalinich C, Harden C, Todeasa C, Jensen C, Kim D, McDonald D, Shepard D,
37 Courchaine E, White EB, Song E, Silva E, Kudo E, Deluiliis G, Rahming H, Park HJ, Matos I, Nouws J,
38 Valdez J, Fauver J, Lim J, Rose KA, Anastasio K, Brower K, Glick L, Sharma L, Sewanan L, Knaggs
39 L, Minasyan M, Batsu M, Petrone M, Kuang M, Nakahata M, Campbell M, Linehan M, Askenase MH,
40 Simonov M, Smolgovsky M, Sonnert N, Naushad N, Vijayakumar P, Martinello R, Datta R, Handoko
41 R, Bermejo S, Prophet S, Bickerton S, Velazquez S, Alpert T, Rice T, Khoury-Hanold W, Peng X,
42 Yang Y, Cao Y, Strong Y, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Cruz CD,
43 Farhadian S, Ko AI, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19.
44 *Nature*. 2020;584(7821):463-469. doi:10.1038/s41586-020-2588-y

45 8. Laing AG, Lorenc A, Barrio I del M del, Das A, Fish M, Monin L, Muñoz-Ruiz M, McKenzie DR,
46 Hayday TS, Francos-Quijorna I, Kamdar S, Joseph M, Davies D, Davis R, Jennings A, Zlatareva I,
47 Vantourout P, Wu Y, Sofra V, Cano F, Greco M, Theodoridis E, Freedman JD, Gee S, Chan JNE,
48 Ryan S, Bugallo-Blanco E, Peterson P, Kisand K, Haljasmägi L, Chadli L, Moingeon P, Martinez L,
49 Merrick B, Bisnauthsing K, Brooks K, Ibrahim MAA, Mason J, Gomez FL, Babalola K, Abdul-Jawad S,
50 Cason J, Mant C, Seow J, Graham C, Doores KJ, Rosa FD, Edgeworth J, Shankar-Hari M, Hayday


- 1 AC. A dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat Med.*
2 2020;26(10):1623-1635. doi:10.1038/s41591-020-1038-6
- 3 9. MD PCH, MD YW, MD PXL, PhD PLR, MD PJZ, MD YH, MD PLZ, MS GF, MDc JX, PhD XG, MD
4 PZC, MD TY, MD JX, MD YW, MD PWW, MD PXX, MD WY, MD HL, MD ML, MS YX, PhD PHG, PhD
5 PLG, MD PJX, MD PGW, MD PRJ, MD PZG, PhD QJ, PhD PJW, MD PBC. Clinical features of
6 patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet.* 2020;395(10223):497-
7 506. doi:10.1016/s0140-6736(20)30183-5
- 8 10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H,
9 Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult
10 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet.*
11 2020;395(10229):1054-1062. doi:10.1016/s0140-6736(20)30566-3
- 12 11. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and
13 coagulation. *The Lancet Respiratory.* Published online April 24, 2020:1-2. doi:10.1016/s2213-
14 2600(20)30216-2
- 15 12. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. *Immunity.* 2020;53(1):19-
16 25. doi:10.1016/j.immuni.2020.06.017
- 17 13. Cardiology ES of. ESC Guidance for the Diagnosis and Management of CV Disease during the
18 COVID-19 Pandemic. Published online April 28, 2020:1-119.
- 19 14. Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and
20 Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. *The American journal of*
21 *cardiology.* Published online March 5, 2020. doi:10.1016/j.amjcard.2020.02.016
- 22 15. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system:
23 acute and long-term implications. *Eur Heart J.* 2020;41(19):1798-1800. doi:10.1093/eurheartj/ehaa231
- 24 16. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis.
25 *Herz.* 2020;45(3):230-232. doi:10.1007/s00059-020-04909-z
- 26 17. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B,
27 Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in
28 Wuhan, China. *Jama Cardiol.* 2020;5(7):802-810. doi:10.1001/jamacardio.2020.0950
- 29 18. Tay JY, Lim PL, Marimuthu K, Sadarangani SP, Ling LM, Ang BSP, Chan M, Leo YS, Vasoo S.
30 De-isolating COVID-19 Suspect Cases: A Continuing Challenge. *Clin Infect Dis.* 2020;71(15):ciaa179.
31 doi:10.1093/cid/ciaa179
- 32 19. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with
33 decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb*
34 *Haemost.* 2020;18(5):1094-1099. doi:10.1111/jth.14817
- 35 20. Wolf D, Zirikli A, Ley K. Beyond vascular inflammation—recent advances in understanding
36 atherosclerosis. *Cell Mol Life Sci.* 2015;72(20):3853-3869. doi:10.1007/s00018-015-1971-6
- 37 21. Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. *Circ Res.* 2019;124(2):315-327.
38 doi:10.1161/circresaha.118.313591
- 39 22. Bahrar H, Bekkering S, Stienstra R, Netea MG, Riksen NP. Innate immune memory in
40 cardiometabolic disease. *Cardiovasc Res.* Published online 2023. doi:10.1093/cvr/cvad030
- 41 23. Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and
42 disease. *Nature.* 2018;18(12):1-12. doi:10.1038/s41577-018-0065-8

- 1 24. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. *Nature reviews*
2 *Cardiology*. 2010;7(2):77-86. doi:10.1038/nrcardio.2009.228
- 3 25. Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and
4 adaptive immunity. *Nat Rev Immunol*. 2022;22(4):251-265. doi:10.1038/s41577-021-00584-1
- 5 26. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for
6 Dimension Reduction. *Arxiv*. Published online 2018.
- 7 27. Gassen SV, Callebaut B, Helden MJV, Lambrecht BN, Demeester P, Dhaene T, Saeys Y.
8 FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Brinkman
9 RR, Aghaeepour Nima, Finak Greg, Gottardo Raphael, Mosmann Tim, Scheuermann RH, eds.
10 *Cytometry Part B: Clinical Cytometry*. 2015;87(7):636-645. doi:10.1002/cyto.a.22625
- 11 28. Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. CombiROC: an
12 interactive web tool for selecting accurate marker combinations of omics data. *Sci Rep-uk*.
13 2017;7(1):45477. doi:10.1038/srep45477
- 14 29. Bombaci M, Rossi RL. Proteomics for Biomarker Discovery, Methods and Protocols. *Methods Mol*
15 *Biology*. 2019;1959:247-259. doi:10.1007/978-1-4939-9164-8_16
- 16 30. Park LM, Lannigan J, Jaimes MC. OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for
17 Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood. *Cytom Part A*.
18 2020;97(10):1044-1051. doi:10.1002/cyto.a.24213
- 19 31. Reizis B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. *Immunity*.
20 2019;50(1):37-50. doi:10.1016/j.immuni.2018.12.027
- 21 32. Ferrari F, Martins VM, Teixeira M, Santos RD, Stein R. COVID-19 and Thromboinflammation: Is
22 There a Role for Statins? *Clinics*. 2021;76:e2518. doi:10.6061/clinics/2021/e2518
- 23 33. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, Investigators A.
24 Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina.
25 *Circulation*. 2002;106(1):24-30. doi:10.1161/01.cir.0000020546.30940.92
- 26 34. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann
27 SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F, Prevention C for DC and,
28 Association AH. Markers of Inflammation and Cardiovascular Disease. *Circulation*. 2003;107(3):499-
29 511. doi:10.1161/01.cir.0000052939.59093.45
- 30 35. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T Cell-directed CC Chemokine
31 TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4*. *J Biol Chem*.
32 1997;272(23):15036-15042. doi:10.1074/jbc.272.23.15036
- 33 36. Hinks TSC, Zhang XW. MAIT Cell Activation and Functions. *Front Immunol*. 2020;11:1014.
34 doi:10.3389/fimmu.2020.01014
- 35 37. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and
36 therapy. *Exp Hematology Oncol*. 2012;1(1):36. doi:10.1186/2162-3619-1-36
- 37 38. Yeap WH, Wong KL, Shimasaki N, Teo ECY, Quek JKS, Yong HX, Diong CP, Bertoletti A, Linn
38 YC, Wong SC. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human
39 monocytes. *Sci Rep-uk*. 2016;6(1):34310. doi:10.1038/srep34310
- 40 39. Wang X, Zhang Y, Wang S, Ni H, Zhao P, Chen G, Xu B, Yuan L. The role of CXCR3 and its
41 ligands in cancer. *Frontiers Oncol*. 2022;12:1022688. doi:10.3389/fonc.2022.1022688

- 1 40. Wilk AJ, Lee MJ, Wei B, Parks B, Pi R, Martínez-Colón GJ, Ranganath T, Zhao NQ, Taylor S,
2 Becker W, Biobank SC 19, Ranganath T, Zhao NQ, Wilk AJ, Vergara R, McKechnie JL, Parte L de la,
3 Dantzer KW, Ty M, Kathale N, Martinez-Colon GJ, Rustagi A, Ivison G, Pi R, Lee MJ, Brewer R, Hollis
4 T, Baird A, Ugur M, Tal M, Bogusch D, Nahass G, Haider K, Tran KQT, Simpson L, Din H, Roque J,
5 Mann R, Chang I, Do E, Fernandes A, Lyu SC, Zhang W, Manohar M, Krempski J, Visweswaran A,
6 Zudock EJ, Jee K, Kumar K, Newberry JA, Quinn JV, Schreiber D, Ashley EA, Blish CA, Blomkalns
7 AL, Nadeau KC, O'Hara R, Rogers AJ, Yang S, Jimenez-Morales D, Blomkalns AL, O'Hara R, Ashley
8 EA, Nadeau KC, Yang S, Holmes S, Rabinovitch M, Rogers AJ, Greenleaf WJ, Blish CA. Multi-omic
9 profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. *J Exp*
10 *Med.* 2021;218(8):e20210582. doi:10.1084/jem.20210582
- 11 41. Breton G, Mendoza P, Hägglöf T, Oliveira TY, Schaefer-Babajew D, Gaebler C, Turroja M, Hurley
12 A, Caskey M, Nussenzweig MC. Persistent cellular immunity to SARS-CoV-2 infection. *J Exp Med.*
13 2021;218(4). doi:10.1084/jem.20202515
- 14 42. Kvedaraite E, Hertwig L, Sinha I, Ponzetta A, Myrberg IH, Lourda M, Dzidic M, Akber M,
15 Klingström J, Folkesson E, Muvva JR, Chen P, Gredmark-Russ S, Brighenti S, Norrby-Teglund A,
16 Eriksson LI, Rooyackers O, Aleman S, Strålin K, Ljunggren HG, Ginhoux F, Björkström NK, Henter JI,
17 Svensson M, Group KKC 19 S, Sandberg JT, Bergsten H, Björkström NK, Brighenti S, Buggert M,
18 Butrym M, Chambers BJ, Chen P, Cornillet M, Cuapio A, Lozano ID, Dzidic M, Emgård J, Flodström-
19 Tullberg M, Gorin JB, Gredmark-Russ S, Haroun-Izquierdo A, Hertwig L, Kalsum S, Klingström J,
20 Kokkinou E, Kvedaraite E, Ljunggren HG, Marquardt N, Lourda M, Maleki KT, Malmberg KJ,
21 Michaëlsson J, Mjösberg J, Moll K, Muvva JR, Norrby-Teglund A, Medina LMP, Parrot T, Radler L,
22 Ringqvist E, Sandberg JK, Sekine T, Soini T, Svensson M, Tynell J, Kries A von, Wullimann D, Perez-
23 Potti A, Rivera-Ballesteros O, Maucourant C, Varnaite R, Akber M, Berglin L, Brownlie D, Loreti MG,
24 Sohlberg E, Kammann T, Henriksson E, Strålin K, Aleman S, Sönnernborg A, Dillner L, Färnert A,
25 Glans H, Naució P, Rooyackers O, Mårtensson J, Eriksson LI, Persson BP, Grip J, Unge C. Major
26 alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. *P Natl Acad*
27 *Sci Usa.* 2021;118(6):e2018587118. doi:10.1073/pnas.2018587118
- 28 43. Koutsakos M, Rowntree LC, Hensen L, Chua BY, Sandt CE van de, Habel JR, Zhang W, Jia X,
29 Kedzierski L, Ashhurst TM, Putri GH, Marsh-Wakefield F, Read MN, Edwards DN, Clemens EB, Wong
30 CY, Mordant FL, Juno JA, Amanat F, Audsley J, Holmes NE, Gordon CL, Smibert OC, Trubiano JA,
31 Hughes CM, Catton M, Denholm JT, Tong SYC, Doolan DL, Kotsimbos TC, Jackson DC, Krammer F,
32 Godfrey DI, Chung AW, King NJC, Lewin SR, Wheatley AK, Kent SJ, Subbarao K, McMahon J,
33 Thevarajan I, Nguyen THO, Cheng AC, Kedzierska K. Integrated immune dynamics define correlates
34 of COVID-19 severity and antibody responses. *Cell Reports Medicine.* 2021;2(3):100208.
35 doi:10.1016/j.xcrm.2021.100208
- 36 44. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical and
37 Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection. *Cytom Part A.*
38 2020;97(9):887-890. doi:10.1002/cyto.a.24188
- 39 45. Mueller YM, Schrama TJ, Ruijten R, Schreurs MWJ, Grashof DGB, Werken HJG van de, Lasinio
40 GJ, Álvarez-Sierra D, Kiernan CH, Eiro MDC, Meurs M van, Brouwers-Haspels I, Zhao M, Li L, Wit H
41 de, Ouzounis CA, Wilmsen MEP, Alofs TM, Laport DA, Wees T van, Kraker G, Jaimes MC, Bockstael
42 SV, Hernández-González M, Rokx C, Rijnders BJA, Pujol-Borrell R, Katsikis PD. Stratification of
43 hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and
44 machine learning. *Nat Commun.* 2022;13(1):915. doi:10.1038/s41467-022-28621-0
- 45 46. Mueller KAL, Langnau C, Günter M, Pöschel S, Gekeler S, Petersen-Urbe Á, Kreisselmeier KP,
46 Klingel K, Bösmüller H, Li B, Jaeger P, Castor T, Rath D, Gawaz MP, Autenrieth SE. Numbers and
47 phenotype of non-classical CD14dimCD16+ monocytes are predictors of adverse clinical outcome in
48 patients with coronary artery disease and severe SARS-CoV-2 infection. *Cardiovasc Res.*
49 2021;117(1):224-239. doi:10.1093/cvr/cvaa328
- 50 47. Winheim E, Rinke L, Lutz K, Reischer A, Leutbecher A, Wolfram L, Rausch L, Kranich J, Wratil
51 PR, Huber JE, Baumjohann D, Rothenfusser S, Schubert B, Hilgendorff A, Hellmuth JC, Scherer C,
52 Muenchhoff M, Bergwelt-Baildon M von, Stark K, Straub T, Brocker T, Keppler OT, Subklewe M, Krug

- 1 AB. Impaired function and delayed regeneration of dendritic cells in COVID-19. *Plos Pathog.*
2 2021;17(10):e1009742. doi:10.1371/journal.ppat.1009742
- 3 48. Zhou R, To KKW, Wong YC, Liu L, Zhou B, Li X, Huang H, Mo Y, Luk TY, Lau TTK, Yeung P,
4 Chan WM, Wu AKL, Lung KC, Tsang OTY, Leung WS, Hung IFN, Yuen KY, Chen Z. Acute SARS-
5 CoV-2 infection impairs dendritic cell and T cell responses. *Immunity.* 2020;53(4):864-877.e5.
6 doi:10.1016/j.immuni.2020.07.026
- 7 49. Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T,
8 Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus
9 D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Müllleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE,
10 Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J,
11 Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, Stillfried S von, Boor P, Demir M,
12 Wesselmann H, Suttrop N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser
13 M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B, Group
14 PC 19 S. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell.*
15 2022;185(3):493-512.e25. doi:10.1016/j.cell.2021.12.040
- 16 50. Mizurini DM, Hottz ED, Bozza PT, Monteiro RQ. Fundamentals in Covid-19-Associated
17 Thrombosis: Molecular and Cellular Aspects. *Frontiers Cardiovasc Medicine.* 2021;8:785738.
18 doi:10.3389/fcvm.2021.785738
- 19 51. Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19
20 infection. *Comput Struct Biotechnology J.* 2021;19:976-988. doi:10.1016/j.csbj.2021.01.034
- 21 52. Meiser A, Mueller A, Wise EL, McDonagh EM, Petit SJ, Saran N, Clark PC, Williams TJ, Pease
22 JE. The Chemokine Receptor CXCR3 Is Degraded following Internalization and Is Replenished at the
23 Cell Surface by De Novo Synthesis of Receptor. *J Immunol.* 2008;180(10):6713-6724.
24 doi:10.4049/jimmunol.180.10.6713
- 25 53. Strauss G, Lindquist JA, Arhel N, Felder E, Karl S, Haas TL, Fulda S, Walczak H, Kirchhoff F,
26 Debatin KM. CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor
27 signaling. *J Exp Med.* 2009;206(6):1379-1393. doi:10.1084/jem.20082363
- 28 54. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C,
29 Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson
30 L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA,
31 Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG,
32 Docherty AB, Harrison EM, Baillie JK, Semple MG, Openshaw PJ, Carson G, Alex B, Bach B, Barclay
33 WS, Bogaert D, Chand M, Cooke GS, Docherty AB, Dunning J, Filipe A da S, Fletcher T, Green CA,
34 Harrison EM, Hiscox JA, Ho AYW, Horby PW, Ijaz S, Khoo S, Klenerman P, Law A, Lim WS, Mentzer
35 AJ, Merson L, Meynert AM, Noursadeghi M, Moore SC, Palmarini M, Paxton WA, Pollakis G, Price N,
36 Rambaut A, Robertson DL, Russell CD, Sancho-Shimizu V, Scott JT, Sigfrid L, Solomon T,
37 Sriskandan S, Stuart D, Summers C, Tedder RS, Thomson EC, Thwaites RS, Turtle LC, Zambon M,
38 Hardwick H, Donohue C, Ewins J, Oosthuyzen W, Griffiths F, Norman L, Pius R, Drake TM, Fairfield
39 CJ, Knight S, Mclean KA, Murphy D, Shaw CA, Dalton J, Girvan M, et al. Risk stratification of patients
40 admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
41 development and validation of the 4C Mortality Score. *Bmj.* 2020;370:m3339. doi:10.1136/bmj.m3339
- 42 55. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T,
43 Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu
44 Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G,
45 Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS,
46 He JX. COVID-19 CMTEG for. Comorbidity and its impact on 1590 patients with COVID-19 in China: a
47 nationwide analysis. *Eur Respir J.* 2020;55(5):2000547. doi:10.1183/13993003.00547-2020

Figure 1





1

2 **Figure 1: UMAP dimensional data analysis of PMBCs using a 36-color antibody panel**


3 **A** Experimental design **B** High-dimensional data analysis of PBMCs from healthy donors (HD, 37),
 4 patients with cardiovascular disease (CVD, 20), and patients with CVD and SARS-CoV-2 infection
 5 (CVD + SARS-CoV2 patients, 37) displayed in two UMAP dimensions. The density plots show
 6 concatenated events from all of the indicated samples. **C** 40 FlowSOM clusters projected onto two
 7 UMAP dimensions. The overlay plot shows concatenated events from all samples. FlowSOM
 8 clusters were assigned to depicted cell populations based on their marker expression (see heatmap
 9 in **D**). **D** Hierarchically clustered heatmap displaying the marker expressions of manually labeled
 10 40 FlowSOM clusters from 37 concatenated HD samples. The marker expression intensity is
 11 displayed on a scale from white (negative) to blue (positive). Each column's max and min are
 12 mapped to this scale, so the values change between markers; consequently, the scale is labeled
 13 with – and + to indicate relative magnitude.

Figure 2


A




B



C



D




1

2 **Figure 2: Differences between immune cell populations of CVD patients compared to**
 3 **SARS-CoV2-infected CVD patients**


4 **A** Volcano plot comparing the frequency of cells in 87 FSOM clusters from CVD and SARS-CoV2-
 5 infected CVD patients using edgeR. Significant different clusters are depicted in green. **B** The
 6 overlay UMAP-plots show concatenated events from CVD (20) and SARS-CoV2-infected CVD (37)
 7 samples highlighting the significantly different clusters from A. **C** Clustered heatmap displaying the
 8 frequency of cells in the FSOM clusters from concatenated samples from CVD (upper row) and
 9 SARS-CoV2-infected CVD patients (lower row). The frequency is displayed per row on a scale from
 10 white (low) to blue (high). **D** Box plots show the abundance of the depicted MC with assigned cell
 11 populations of the individual samples from CVD and SARS-CoV2-infected CVD patients. Data were
 12 analyzed using Mann-Whitney non-parametric test. Significant differences between the two patient
 13 cohorts are marked with stars (* > 0.05; ** > 0.01; *** > 0.001; **** > 0.0001). MC, metacluster

Figure 3


A




B



C



D




1

2 **Figure 3: Differences between immune cell populations in mild, moderate, and severe**
 3 **SARS-CoV2-infected CVD patients**

4 **A** Volcano plots comparing the frequency of cells in the 87 FSOM clusters from mild (10), moderate
 5 (20), and severe (7) SARS-CoV2-infected CVD patients using edgeR. Significant different clusters
 6 are depicted in green. **B** The overlay UMAP plot shows concatenated events from mild (10),
 7 moderate (20), and severe (7) SARS-CoV2-infected CVD patients highlighting the significantly
 8 different MCs from A. **C** Clustered heatmap displaying the frequency of cells in the FSOM clusters
 9 from concatenated samples from severe (upper row), moderate (middle row), and mild SARS-
 10 CoV2-infected CVD patients (lower row). The frequency is displayed per row on a scale from white
 11 (low) to blue (high). **D** Box plots show the abundance of the depicted MC with assigned cell
 12 populations of the individual samples. Data were analyzed using Kruskal-Wallis non-parametric
 13 test with Dunn's post-test. Significant differences between the patient cohorts are marked with stars
 14 (* > 0.05; ** > 0.01; *** > 0.001).

Figure 4



1

2 **Figure 4: Correlation of immune cell abundance with disease severity**

3 **A** Volcano plot comparing the frequency of cells in the 40 assigned cell populations (from Fig. 1)
 4 from mild (10), moderate (20), and severe (7) SARS-CoV2-infected CVD patients using edgeR.
 5 Significantly different cell populations are depicted in green. **B** The overlay UMAP plot shows
 6 concatenated events from mild (10), moderate (20), or severe (7) SARS-CoV2-infected CVD
 7 patients highlighting the significantly different cell populations from A. **C** CombiROC analysis using
 8 the frequencies of the significantly different cell populations from A. Patients stratified for a mild
 9 course of infection compared either with severely stratified patients (left) or the combination of
 10 moderate and severe stratified patients (right). **D** Orthogonal partial-least square (OPLS) analysis
 11 comprising immune cell populations and cytokine/chemokine plasma levels of patients with SARS-
 12 CoV2 infection. Dots represent single study subjects and are colored by disease severity (with mild
 13 = blue, moderate = yellow, severe = red points). X-axis and Y-axis show the T score as well as the
 14 percentage of explained variance.